scholarly journals Updated Cutoff Values of Basal Serum Calcitonin to Discriminate True Medullary Thyroid Cancer from Other Conditions of Hypercalcitoninemia

2021 ◽  
Author(s):  
Qianhui Liu ◽  
Xin Nie ◽  
Yong He ◽  
Guixing Li
Keyword(s):  
Thyroid Carcinoma ◽  
Disease Burden ◽  
Chronic Renal Disease ◽  
Tumor Diameter ◽  
Serum Calcitonin ◽  
West China Hospital ◽  
West China ◽  
Medullary Thyroid ◽  
Cutoff Values ◽  
The Relationship

Abstract Background Calcitonin (Ctn) is a tumor marker of medullary thyroid carcinoma (MTC). However, serum Ctn cutoff values for MTC diagnosis are still under discussion. This study aimed to identify the cutoff values of Ctn and explore the relationship between two tumor markers (Ctn and carcinoembryonic antigen (CEA)) and disease burden. Methods This was a retrospective study conducted in West China Hospital of Sichuan University. We included 61 MTC patients and 235 non-MTC patients with nonspecific elevation of Ctn (> 9.52 pg/mL for males and > 6.40 pg/mL for females) and collected patients’ demographic information, essential serological indicators, cervical ultrasound and pathological reports. Results Unlike MTC, papillary thyroid carcinoma (40.85%), uremia (18.73%), chronic renal disease (10.21%) and inflammation (8.94%) commonly occurred with hypercalcitoninemia. The Ctn cutoff values were 38.24 pg/mL for males and 26.00 pg/mL for females. The Ctn level was found to be positively related to the largest tumor diameter (r = 0.702). Serum Ctn levels were significantly higher in patients with lymph node metastasis than in those without (P < 0.05), but CEA levels did not differ (P > 0.05). Conclusion The best Ctn cutoff values for Chinese people to discriminate MTC from other hypercalcitoninemia conditions are 38.24 pg/mL for males and 26.00 pg/mL for females.

scholarly journals Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy

2013 ◽  
Vol 168 (2) ◽  
pp. 113-118 ◽  
Author(s):  
G Hajje ◽  
I Borget ◽  
S Leboulleux ◽  
C Chougnet ◽  
A Al Ghuzlan ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Carcinoembryonic Antigen ◽  
Medullary Thyroid Carcinoma ◽  
Surrogate Marker ◽  
Progression Free Survival ◽  
Cytotoxic Chemotherapy ◽  
Serum Calcitonin ◽  
Free Survival ◽  
Medullary Thyroid ◽  
The Relationship

IntroductionThe prognostic value of serum calcitonin (CT) and carcinoembryonic antigen (CEA) doubling time has been recently demonstrated in medullary thyroid carcinoma (MTC) patients. No study has yet validated the surrogate role of these markers for survival during treatment. The aim of this study was to evaluate, in patients with advanced MTC treated with cytotoxic chemotherapy, the relationship between early changes of serum CT or CEA levels and progression-free survival (PFS).Patients and methodsThe files of 28 consecutive metastatic MTC patients with progressive disease, treated with cytotoxic chemotherapy in a single tertiary referral center between 2000 and 2010, were retrospectively reviewed. Serum CT and CEA measurements and radiological Response Evaluation Criteria in Solid Tumors (RECIST) evaluations were collected every 3 months. The relationship between changes in serum CT and CEA levels at 3 months, defined by an increase or a decrease of at least 20%, and PFS according to RECIST 1.0, was estimated using Kaplan–Meier curves and log-rank test.ResultsThe median follow-up for the 28 patients was 68 months. According to RECIST, a partial response, a stabilization or a progression was observed in 14, 43, and 43% of cases respectively. Median PFS from the initiation of cytotoxic chemotherapy was 4.5 months. Median PFS among patients with and without significant CT increase at 3 months was 4.6 and 3.3 months respectively (P=0.75). Median PFS among patients with a significant CEA increase at 3 months was 2.7 months, whereas it was 19.1 months in patients in whom CEA did not increase (P=0.02).ConclusionAt 3 months, an increase of serum CEA but not of CT levels appears as a valuable surrogate marker of short PFS in MTC patients treated with cytotoxic chemotherapy. A prospective validation is expected.

scholarly journals Usefulness of preoperative serum calcitonin in patients with nodular thyroid disease without suspicious history or cytology for medullary thyroid carcinoma

2013 ◽  
Vol 57 (4) ◽  
pp. 312-316 ◽  
Author(s):  
Pedro Weslley Rosário ◽  
Gustavo Cancela Penna ◽  
Kamilla Brandão ◽  
Bárbara Érika Souza
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Multiple Endocrine Neoplasia ◽  
Multiple Endocrine Neoplasia Type ◽  
Serum Calcitonin ◽  
Medullary Thyroid ◽  
Endocrine Neoplasia ◽  
Preoperative Serum ◽  
History Of

OBJECTIVE: To evaluate the usefulness of preoperative serum calcitonin (sCT) in patients with nodular disease without suspicion of medullary thyroid carcinoma (MTC) in history or cytology. PATIENTS AND METHODS: sCT was measured before thyroidectomy in 494 patients with nodular disease who had no family history of MTC or multiple endocrine neoplasia type 2, and no cytological suspicion of MTC. RESULTS: Basal sCT was < 10 ng/mL in 482 patients and none of them had MTC. One patient with basal sCT > 100 pg/mL had MTC. Among the 11 patients with basal sCT between 10 and 100 pg/mL, MTC was diagnosed in only one. The two patients with MTC were submitted to total thyroidectomy, combined with elective lymph node dissection indicated exclusively based on hypercalcitoninemia, and sCT was undetectable after six months. CONCLUSIONS: Preoperative sCT is useful for the detection of sporadic MTC in patients with nodular disease, even in the absence of suspicious history or cytology.

scholarly journals Serum calcitonin negative Medullary thyroid carcinoma

2006 ◽  
Vol 4 (1) ◽  
Author(s):  
Michael Sand ◽  
Marcos Gelos ◽  
Daniel Sand ◽  
Falk G Bechara ◽  
Gerd Bonhag ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Serum Calcitonin ◽  
Medullary Thyroid

Nodal Disease Burden and Outcome of Medullary Thyroid Carcinoma

2019 ◽  
Vol 229 (4) ◽  
pp. S78-S79
Author(s):  
Lindsey E. Moses ◽  
Jamie R. Oliver ◽  
Janine M. Rotsides ◽  
Qianhui Shao ◽  
Kepal N. Patel ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Disease Burden ◽  
Nodal Disease ◽  
Medullary Thyroid

Disappearance Rate of Serum Calcitonin after Total Thyroidectomy for Medullary Thyroid Carcinoma

1994 ◽  
Vol 9 (1) ◽  
pp. 21-24 ◽  
Author(s):  
L. Fugazzola ◽  
A. Pinchera ◽  
F. Luchetti ◽  
P. Iacconi ◽  
P. Miccoli ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Total Thyroidectomy ◽  
Medullary Thyroid Carcinoma ◽  
Half Life ◽  
Slow Component ◽  
General Rule ◽  
Disappearance Rate ◽  
Serum Calcitonin ◽  
Medullary Thyroid ◽  
Undetectable Serum

We studied the half-life of serum calcitonin (CT) in patients subjected to total thyroidectomy for medullary thyroid carcinoma (MTC). One patient showed a rapid serum CT component with a half-life of 3 hours and a slow component with a half-life of 30 hours; in another case only the 30-hour component was found. By chromatography of tumor extracts, we found that all the immunoreactive CT had a molecular weight of 3,600. After surgery, normalization of serum CT was achieved within 15 days in 4 patients, at 3 months and at 6 months in 2 other patients, while 1 patient never normalized. Normalization of serum CT after surgery is not an index of definitive cure in MTC, as demonstrated by one patient who relapsed 3 months after normalization of serum CT. However, as a general rule, patients who reach undetectable serum CT levels soon after surgery, are those having the best prognosis.

C-Cell Hyperplasia and Medullary Thyroid Carcinoma in Patients Routinely Screened for Serum Calcitonin

1998 ◽  
Vol 22 (6) ◽  
pp. 722-728 ◽  
Author(s):  
Klaus Kaserer ◽  
Christian Scheuba ◽  
Nikolaus Neuhold ◽  
Andreas Weinhäusel ◽  
Heinrich Vierhapper ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Cell Hyperplasia ◽  
Serum Calcitonin ◽  
Medullary Thyroid ◽  
C Cell Hyperplasia ◽  
C Cell
Sign in / Sign up

Export Citation Format

Share Document